Colchicine and pseudogout

González, Tomás; Gantes, M

doi:10.1002/art.1780251226

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Treatment Of Cppdmentioning

confidence: 99%

“…Studies have shown that oral colchicine may be effective in reducing the number of flares in CPPD patients ( 30 , 31 ). A low dose of colchicine (0.6 mg BID) has been found to decrease the flare-up ratio from 3.2/patient/year to 1/patient/year ( 30 ), while in another study colchicine has been shown to reduce the annual attacks from 9.3 to 2.4 in 12 patients ( 31 ). Finally, a study of 39 patients with knee OA showed that adding colchicine 0.5 mg twice daily to the existing treatment plan of intra-articular glucocorticoids and oral piroxicam improved pain relief ( 32 ).…”

Section: Treatment Of Cppdmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in the therapeutic management of calcium pyrophosphate deposition disease

Voulgari,

Venetsanopoulou,

Drosos

2024

Front. Med.

View full text Add to dashboard Cite

Calcium pyrophosphate deposition (CPPD) disease is a form of crystal-induced arthropathy that arises from the accumulation of calcium pyrophosphate crystals within joints and soft tissues. This process leads to inflammation and damage to the affected joints. It can present asymptomatically or as acute or chronic inflammatory arthritis. Risk factors and comorbidities, including prior joint injury, osteoarthritis, hereditary or familial predisposition, and metabolic diseases, should be evaluated in CPPD cases. The management of CPPD remains a challenge in the sparsity of randomized controlled trials. The lack of such trials makes it difficult to establish evidence-based treatment protocols for CPPD. This review provides an overview of the current pharmacological management of CPPD, focusing on reducing inflammation, alleviating symptoms, and preventing acute flares. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine are effective in managing acute CPP arthritis. Colchicine may also be used prophylactically to prevent recurrent flares. In cases where other treatments have failed, anakinra, an interleukin-1 receptor antagonist, can be administered to alleviate acute flares. The management of chronic CPP inflammatory arthritis includes NSAIDs and/or colchicine, followed by hydroxychloroquine, low-dose glucocorticoids, and methotrexate, with limited data on efficacy. Tocilizumab can be used in refractory cases. In small studies, synovial destruction using intra-articular injection of yttrium 90 can decrease pain. To date, no disease-modifying therapies exist that reduce articular calcification in CPPD.

show abstract

Section: Treatment Of Cppdmentioning

confidence: 99%

Section: Treatment Of Cppdmentioning

confidence: 99%

Recent advances in the therapeutic management of calcium pyrophosphate deposition disease

Voulgari,

Venetsanopoulou,

Drosos

2024

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Its mechanism of action involves blocking microtubule polymerization, interfering with the metaphase of the cells, and inhibiting neutrophil chemotaxis and innate immune responses [ 33 , 34 ]. A small prospective cohort study composed of 12 patients, conducted in 1978 in Spain, reported that the frequency of acute CPP crystal attacks was reduced to an average of 2.4 from 9.3 attacks (P < 0.05) after treatment with daily 1 mg of oral colchicine for one year [ 33 , 35 ]. Other studies have also shown the utility of colchicine as a prophylactic agent against recurrent acute CPP arthritis at a dose of 0.6 mg twice daily [ 36 ].…”

Section: Reviewmentioning

confidence: 99%

A Narrative Review of Chondrocalcinosis: Clinical Presentation, Diagnosis, and Therapies

Kim,

Afroz,

Gillespie

et al. 2024

Cureus

View full text Add to dashboard Cite

Calcium pyrophosphate deposition disease is categorized into radiographic chondrocalcinosis, acute calcium pyrophosphate arthritis, chronic calcium pyrophosphate arthritis, and osteoarthritis with calcium pyrophosphate deposition. These entities collectively are characterized by the deposition of calcium into joints, which then may cause localized and systemic inflammation, resulting in pain and swelling in the affected joints. Patients with the ANKH gene are more susceptible to the development of CPP arthritis as are those with primary hyperparathyroidism, hypomagnesemia, and hemochromatosis. Radiographic chondrocalcinosis is asymptomatic. Acute calcium pyrophosphate arthritis results in self-limited periods of joint pain and swelling in the affected joint. Along with localized inflammation, there may also be systemic inflammation characterized by fever and elevated inflammatory markers. Chronic calcium pyrophosphate arthritis results in periods of quiescence interrupted by flares that are identical to acute periods of disease. Osteoarthritis associated calcium pyrophosphate arthritis presents with chronic pain well described in osteoarthritis with periods of acute flares. In 2023, a joint effort by the American College of Rheumatology and the European League Against Rheumatism developed guidelines meant to aid in the recognition of calcium pyrophosphate deposition diseases. The diagnosis is made if there is proof of either crowned dens syndrome or synovial fluid analysis demonstrating calcium pyrophosphate crystals or when more than 56 points are summed utilizing the criteria described in the guidelines. Radiographic chondrocalcinosis requires no therapy. Acute calcium pyrophosphate arthritis is treated with the goal of aborting the flare. Treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, oral corticosteroids, parenteral corticosteroids, intraarticular corticosteroids, IL-1 inhibitors, or parenteral adrenocorticotropic hormone (ACTH). The goal in treatment for chronic calcium pyrophosphate arthritis is the suppression of acute flares. The drugs used for acute flare treatment may be given as maintenance therapy with the additional options of methotrexate and hydroxychloroquine.

show abstract

Management of calcium pyrophosphate crystal deposition disease: A systematic review

Parperis

Papachristodoulou

Kakoullis

et al. 2021

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

Colchicine and pseudogout

Cited by 5 publications

References 0 publications

Recent advances in the therapeutic management of calcium pyrophosphate deposition disease

Recent advances in the therapeutic management of calcium pyrophosphate deposition disease

A Narrative Review of Chondrocalcinosis: Clinical Presentation, Diagnosis, and Therapies

Management of calcium pyrophosphate crystal deposition disease: A systematic review

Contact Info

Product

Resources

About